(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 1 413 332 A1

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication:
28.04.2004 Bulletin 2004/18

(21) Application number: **02745439.6**

(22) Date of filing: **01.07.2002**

(51) Int Cl.[7]: **A61P 15/10**, A61K 31/185

(86) International application number:
PCT/ES2002/000325

(87) International publication number:
WO 2003/004097 (16.01.2003 Gazette 2003/03)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **02.07.2001 ES 200101535**

(71) Applicant: **LABORATORIOS DEL DR. ESTEVE, S.A.**
08041 Barcelona (ES)

(72) Inventors:
- **ESTEVE-SOLER, José**
  E-08041 Barcelona (ES)
- **SAENZ DE TEJADA-GORMAN, Inigo**
  E-08041 Barcelona (ES)

(74) Representative: **Carpintero Lopez, Francisco**
HERRERO & ASOCIADOS, S.L.
Alcalá, 35
28014 Madrid (ES)

(54) USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID DERIVATIVES IN THE PRODUCTION OF A MEDICAMENT USED TO POTENTIATE THE EFFECT OF OTHER DRUGS IN THE TREATMENT OF ERECTILE DYSFUNCTION

(57) The present invention refers to the use of derivatives of 2,5-dihidroxybenzenosulphonic acids of general formula (I), to develop medicinal products of therapeutic value to enhance the effects of phosphodiesterase-5 including sildenaphyl, vardenaphyl and IC-351, of apomorphine, of nitric oxide donors including amyl nitrate, nitroglycerine, nitroprussiate, nitrosothioles and nicorandyl, of the compounds that increase the level of cyclic GMP in the penile tissue and of other compounds used to facilitate penile erection in man.



(I)

EP 1 413 332 A1

Description

Field of the Invention

[0001] The present invention refers to the use of 2,5-dihydroxybenzenosulphonic acids of general formula (I) in the production of medicinal products of therapeutic value to enhance the effects of phosphodiesterase-5 inhibitors including sildenaphyl, vardenaphyl and IC-351, of apomorphine, nitric acid donors including amyl nitrate, nitroglycerine, nitroprussiate, nitrosothiols and nicorandyl, of compounds that increase cyclic GMP levels in the penile tissue and of other compounds used to facilitate penile erection in man.



(I)

Detailed description of the invention

[0002] The present invention refers to the use of derivatives of 2,5 dihydroxybenzenosulphonic acids in the production of drugs of therapeutic value to enhance the effects of phosphodiesterase inhibitors including sildenaphyl, vardenaphyl and IC-351, of apomorphine, of nitric oxide donors including amyl nitrate, nitroglycerine, nitroprussiate, nitrosothioles and nicorandyl, of compounds that increase the level of cyclic GMP in penile tissue and of other compounds used to facilitate penile erection in man.

[0003] In recent studies, we have shown that compounds of general formula (I) exert effects on the resistance arteries of the human penis that result in enhancement of the effects of phosphodiesterase-5 inhibitors, such as sildenaphyl, and of apomorphine, of the nitric acid donors and of other products destined to facilitate penile erection in man.

[0004] It is known that the therapeutic response to sildenaphyl is variable in different patients and often does not exceed 50% [MS Rendell et al, JAMA 1999, 281: 421-426; R Virag, Urology 1999; 54: 1073-1077], which creates a deficient therapeutic situation.

[0005] The compounds referred to in the present invention have general formula (I):



(I)

in which:

- R represents a hydrogen atom or a sulphonate group (SO_3^-);
- B represents a calcium ion (Ca^{++}) or a diethylammonium group [$H_2N^+(C_2H_5)_2$];
- n represents 1 or 2; and
- m represents 1 or 2.

[0006] The compounds of the following examples are prepared according to the procedures described previously:

Example 1

[0007] Calcium 2,5-dihidroxybenzenosulphonate (Calcium dobesylate). "The Merck Index", 12 edition, Merck & Co., Whitehorse Station, N.J., USA, 1996.

Example 2

[0008] Diethylammonium 2,5-dihidroxybenzenosulphonate (Ethamsylate). "The Merck Index", 12 edition, Merck & Co., Whitehouse Station, N.J., USA, 1996.

Example 3

[0009] Bis-diethylammonium 2,5-dihidroxybenzene-1,4-disulphonate (Bis-diethylammonium persilate). French patent FR 73/17709 (publication number 2.201.888).

[0010] To study the enhancing effect of medicinal products used to facilitate penile erection in man a series of studies were carried out of the resistance arteries of the human penis, obtained from patients submitted to penile prosthesis implantation.

[0011] Specimens of human cavernous bodies of the penis were obtained from patients with impotence while these were intervened for prosthetic implantation, as described previously (Gupta et al.; Br. J. Pharmacol., 116: 2201, 1995). The tissues were deposited in M-400 solution (pH 7.4; 400 mOsm/kg. Composition in w/v:

4.19% manitole, 0.2% KH_2PO_4, 0.97% K_2HPO_4·3 H_2O, 0.11% KCl and 0.08% $NaHCO_3$) at 4°C at the moment of explant and were transported to the laboratory to be used within the following 16 h.

[0012] The resistance arteries of the penis, helicine arteries (with a luminal diameter of 150-400 μm), which are terminal branches of the deep arteries of the penis, were dissected carefully removing the surrounding trabecular tissue and were cut into 2 mm long arterial segments that were arranged on two wires of 40 μm diameter in a Halpern-Mulvany myograph (J.P. Trading, Aarhus, Denmark) to record isometric pressure. The cavities contained physiological saline solution (PSS) through which a mixture of 95% O_2/5% CO_2 was continually passed to maintain this oxygenated and to maintain the pH at around 7.4. The arteries were contracted with 1 μM of noradrenaline and their relaxation responses were assessed after adding to the cavities increasing amounts of the different compounds. Transmural electrical stimulation (TES) was carried out using two electrodes placed parallely to the arterial segment and connected to a stimulator with a direct output current (50 mA). Squared pulses were applied of 0.3 ms duration in relays of 15 s with variable frequency (0.5, 1, 2 and 6 Hz).

Effects on the relaxation of resistance arteries of the human penis enhanced by a specific nitric oxide donor.

[0013] Calcium dobesylate at a concentration of 10μM increases, in a statistically significant manner, the relaxation produced by different concentrations of sodium nitroprussiate (SNP), a known nitric oxide donor (fig 1).

Effects on the relaxation of resistance arteries of the human penis induced by sildenaphyl.

[0014] Calcium dobesylate at a concentration of 10 μM increases, in a statistically significant manner, the relaxation produced by different concentrations of the inhibitor of 5-sidenaphyl phospodiesterase (fig. 2).

Effects on the relaxation of resistance arteries of the human penis induced by electrical stimulation of nitrergic terminations.

[0015] Calcium dobesylate at a concentration of 10 μM increases, in a statistically significant manner, the relaxation produced by electrical stimulation at increasing frequencies of the nitrergic terminations in resistance arteries of the human penis (fig 3). This effect is similar and even greater than that produced by sildenaphyl at a concentration of 10 nM (fig 4).

[0016] Calcium dobesylate, at a concentration of 10 μM, increases, in a statistically significant manner, the effects of 10 nM of sildenaphyl on the relaxation produced by electrical stimulation at increasing frequencies of the nitrergic terminations in resistance arteries of the human penis (fig 4).

Claims

1. The use of a derivative of a 2,5-dihidroxybenzenosulphonate acid of general formula (I):



(I)

in which

- R represents a hydrogen atom or a sulphonate group (SO_3^-);
- B represents a calcium ion (Ca^{++}) or a diethylammonium group [$H_2N^+(C_2H_5)_2$];
- n represents 1 or 2; and
- m represents 1 or 2.

in the production of medicinal products to enhance the effects of phosphodiesterase-5 inhibitors, of apomorphine, of nitric oxide donors, of compounds that increase the level of cyclic GMP in penile tissue and of other compounds used to facilitate penile erection in man.

2. The use, according to Claim 1, of 2,5-dihidroxybenzenosulphonate of calcium (calcium dobesylate) to produce medicinal products to enhance the effects of phosphodiesterase-5 inhibitors, of apomorphine, of nitric oxide donors, of compounds that increase the level of cyclic GMP in penile tissue and of other compounds used to facilitate penile erection in man.

3. The use, according to Claim 1, of diethylammonium 2,5-dihidroxybenzenosulphonate (Ethamsylate) to produce the medicinal products used to enhance the effects of phosphodiesterase-5 inhibitors, of apomorphine, of nitric oxide donors, of compounds that increase the level of cyclic GMP in the penile tissue and of other compounds used to facilitate penile erection in man.

4. Use, according to Claim 1, of bis-diethylammonium 2,5-dihidroxybenzeno-1,4-disulphonate (Per-

sylate) in the production of medicinal products to enhance the effects of phosphodiesterase-5 inhibitors, of apomorphine, of nitric oxide donors, of compounds that increase the levels of cyclic GMP in penile tissue and of other compounds used to facilitate penile erection in man.


Human Penile Resistance Arteries
o control
• dobesilate 10μM
Δ sildenafil 10 nM
▲ dobesilate+sildenafil
*** p<0.005 vs control
††† p<0.005 vs dobesilate or sildenafil
% Relaxation
0
-20
-40
-60
-80
-100
***
†††
n=5
-9
-8
-7
-6
-5
-4
-3
-2
log M [SNP]

FIG.1


Human Penile Resistance Arteries
0
-20
-40
-60
-80
-100
-120
% Relaxation
o vehicle
● dobesilate 10μM
***
n=5
***p<0.005 vs vehicle
-9
-8
-7
-6
-5
-4
-3
log M [sildenafil]

FIG.2


Human Penile Resistance Arteries
control
vehicle
% Relaxation
0
-20
-40
-60
-80
n=6
0,5
1
2
4
8
16
Frequency (Hz)
control
dobesilate 10µM
% Relaxation
n=5
p<0.01
Frequency (Hz)

FIG.3


Human Penile Resistance Arteries
control
sildenafil 10 nM
% Relaxation
0
-20
-40
-60
-80
n=6
0,5
1
2
4
8
16
Frequency (Hz)
control
dobesilate+sildenafil
% Relaxation
n=6
p<0.001
Frequency (Hz)

FIG.4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/ES 02/00325

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P15/10, A61K 31/185

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9737647 A (LABORATORIOS DE DR. ESTEVE, S.A.) 16.10.1997. (16 October 1997) See the whole document, especially claims and page 1, line 13 -page 2, line 9.	1-4
A	FR 2511598 A (GAURI, K.K.) (25 February 1983). Page 1, lines 9-10; claim 1, lines 1-9.	1,2
A	WO 9829103 A (BIOGAL GYOGYSZERGYAR RT) 09.07.1998. Claims 5-8. (9 July 1998)	1,2
A	(23 November 1992) SU 1776408 A (ODESS PIROGOV INST.) 23.11.1992 (abstract) World Patents Index [on line]. London (United Kingdom): Derwent Publications, Ltd. [recovered on 23.08.2002]. Access n. 1993-402392. (23 August 2002)	1,2

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
30 August (30.08.2002)	02 October 2002 (02.10.2002)
Name and mailing address of the ISA/	Authorized officer
Facsimile No.	Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/ES 021/00325

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 3681503 A (ESTEVE-SUBIRANA y col.) 01.08.1972. See the whole document. (24 February 1981)	1,3
A	US 4252821 A (FARINE J.C. y SCHULTHESS, A.) 24.02.1981. Abstract; column 1, lines 1-22. (01 August 1972)	1,4

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/ES 02/00325

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9737647 A	16.10.1997	ES 2127132 A	01.04.1999
		FR 2747040 A	10.10.1997
		US 6147112 A	14.11.2000
		US 6403643 A	11.06.2002
		JP 2000508308 T	04.07.2000
		AU 2695697 A	29.10.1997
		NO 0984572 A	30.9.1998
FR 2511598 A	25.02.1983	DE 3231284 A	07.04.1983
		GB 2105587 A	30.03.1983
		JP 58043924 A	14.03.1983
		US 4511557 A	16.04.1985
WO 9829103 A	09.07.1998	US 5994411 A	30.11.1999
		EP 0930879 A	28.07.1999
		CA 2244907 A	09.07.1998
		CN 1232390 A	20.10.1999
		HU 9603631 A	28.09.1998
SU 1776408 A	23.11.1992	NONE	
US 3681503 A	01.08.1972	GB 1323437 A	18.07.1973
		FR 2060557 A	18.06.1971
		DE 1949313 A	08.04.1971
		SE 0374446 A	03.03.1975
		NL 7013954 A	01.04.1971
		CH 514213 A	15.10.1971
		BE 754552 A	18.01.1971
		AT 313036B B	15.12.1973
US 4252821 A	24.02.1981	JP 56092210 A	25.07.1981

Form PCT/ISA/210 (patent family annex) (July 1992)